BioSpace News Archive

Covectra, a leader in track and trace solutions, today announced the Covectra Verification Router Service (VRS), a complete API solution enabling pharmaceutical brands to validate the status of a returned product to ascertain its resell ability and ensure regulatory compliance with the upcoming Drug Supply Chain and Security Act (DSCSA) saleable returns requirement.

Acepodia, a biotechnology company developing cancer immunotherapies based on its novel ACC (Antibody Cell Conjugation) technology platform, today announced that it presented preclinical data on ACE1702, a natural killer cell (NK cell) therapy being developed as a treatment for HER2-expressing solid tumors. The data was presented in a digital

Medigene AG (Medigene, FSE: MDG1), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, presents insights from preclinical studies on its PD1-41BB switch receptor at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II taking place from 22 – 24 June 2020. The e-poster is available online today on the first day of the virtual conference as well as

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced the presentation of preclinical data and provided a program update on their ongoing Phase 1b/2 study evaluating the combination of BeiGene’s investigational RAF dimer inhibitor, lifirafenib,

Data demonstrate potential of Amunix’s XPAT platform to significantly widen therapeutic index, and address on-target, off-tumor toxicity that has hindered application of T cell engagers to treat solid tumors Prodrug XPATs demonstrated >1000 fold increase in tolerated exposures versus traditional T cell engagers Amunix’s lead program, AMX-818, an XPAT T cell engager targeting HER2+ solid tumors, continues to progress toward the clinic MOUNTAIN VIEW, Calif., June 22, 2020 (GLOBE NEWS

- NL-201 demonstrates durable antitumor activity in animal tumor models - - NL-201 and targeted variants improve outcomes when combined with CAR-T cells in vivo - - Conditional activation of de novo proteins using split molecule technology may increase therapeutic index - - Company to host Investor R&D Showcase Tuesday, June 23 at 3:30 p.m. PT / 6:30 p.m. ET - SEATTLE, June 22, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical com

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, presents new data at the American Association for Cancer Research (AACR) Virtual Annual Meeting II demonstrating that its LUNAR-2 liquid biopsy is a highly sensitive test that can detect early-stage colorectal cancer (CRC).

Preclinical Data Supports Expanded Therapeutic Index and Provides Rationale for Ongoing Clinical Studies

SOTIO and Cytune Pharma from the PPF Group, today presented new preclinical data highlighting the therapeutic potential of SO-C101, an IL-15 superagonist, as a monotherapy and in combination with PD-1 inhibitors in multiple tumor models. The data were presented in a virtual poster presentation at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II. “SO-C101 is a highly promising modality in immuno-oncology giv

Data demonstrate the ablation of solid tumors with nitric oxide All tumor-bearing mice treated with nitric oxide rejected a second tumor challenge, suggesting induction of an anti-tumor immune response GARDEN CITY, N.Y., June 22, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections an